SpringWorks TherapeuticsSWTX
About: SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
Employees: 305
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
54% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 26
45% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 60
7% more funds holding
Funds holding: 206 [Q2] → 220 (+14) [Q3]
0.87% more ownership
Funds ownership: 107.31% [Q2] → 108.19% (+0.87%) [Q3]
14% less capital invested
Capital invested by funds: $3B [Q2] → $2.58B (-$420M) [Q3]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 4 (-2) [Q3]
51% less call options, than puts
Call options by funds: $4.46M | Put options by funds: $9.02M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Robert Burns 43% 1-year accuracy 69 / 161 met price target | 103%upside $74 | Buy Maintained | 12 Nov 2024 |
JP Morgan Anupam Rama 40% 1-year accuracy 25 / 62 met price target | 87%upside $68 | Overweight Maintained | 4 Sept 2024 |
HC Wainwright & Co. Robert Burns 43% 1-year accuracy 69 / 161 met price target | 109%upside $76 | Buy Reiterated | 28 Aug 2024 |
Financial journalist opinion
Based on 12 articles about SWTX published over the past 30 days
